HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hydrocodone Bitartrate And Homatropine Methylbromide, and when can generic versions of Hydrocodone Bitartrate And Homatropine Methylbromide launch?
Hydrocodone Bitartrate And Homatropine Methylbromide is a drug marketed by Abhai Llc, Actavis Mid Atlantic, Apozeal Pharms, Ivax Sub Teva Pharms, Nostrum Labs Inc, Novel Labs Inc, Padagis Us, Pai Holdings Pharm, and Wockhardt Bio Ag. and is included in nine NDAs.
The generic ingredient in HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE is homatropine methylbromide; hydrocodone bitartrate. There are five drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the homatropine methylbromide; hydrocodone bitartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hydrocodone Bitartrate And Homatropine Methylbromide
A generic version of HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE was approved as homatropine methylbromide; hydrocodone bitartrate by AVANTHI INC on August 7th, 2017.
Summary for HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE
US Patents: | 0 |
Applicants: | 9 |
NDAs: | 9 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE? | HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE excipients list |
DailyMed Link: | HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE at DailyMed |
Pharmacology for HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE
Drug Class | Opioid Agonist |
Mechanism of Action | Opioid Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE
US Patents and Regulatory Information for HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abhai Llc | HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE | homatropine methylbromide; hydrocodone bitartrate | SYRUP;ORAL | 207487-001 | Feb 21, 2017 | AA | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Padagis Us | HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE | homatropine methylbromide; hydrocodone bitartrate | SYRUP;ORAL | 205731-001 | Feb 15, 2017 | AA | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Ivax Sub Teva Pharms | HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE | homatropine methylbromide; hydrocodone bitartrate | SYRUP;ORAL | 040285-001 | Jul 19, 1999 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pai Holdings Pharm | HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE | homatropine methylbromide; hydrocodone bitartrate | SYRUP;ORAL | 040613-001 | Feb 8, 2008 | AA | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Actavis Mid Atlantic | HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE | homatropine methylbromide; hydrocodone bitartrate | SYRUP;ORAL | 088017-001 | Jul 5, 1983 | AA | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Apozeal Pharms | HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE | homatropine methylbromide; hydrocodone bitartrate | SYRUP;ORAL | 204765-001 | Mar 6, 2017 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novel Labs Inc | HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE | homatropine methylbromide; hydrocodone bitartrate | SYRUP;ORAL | 203535-001 | Feb 13, 2017 | AA | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |